A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

The World Health Organization (WHO) has issued new guidelines recommending the twice-yearly use of injectable lenacapavir ...

The World Health Organization now recommends lenacapavir, a twice-yearly injectable HIV prevention drug, especially for high-risk groups. This endorse ...

The future of the global HIV response risks being undermined by shrinking funding and wavering political will, health leaders have warned as the International AIDS Society (IAS) Conference on HIV ...

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and developing AIDS should be made available "immediately" at pharmacies, clinics and ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

IAS 2025, the 13th IAS Conference on HIV Science, opened today with a call to accelerate access to long-acting HIV prevention and treatment innovations amid growing global funding challenges. Four ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

The World Health Organisation (WHO) has called for the immediate global rollout of a breakthrough HIV drug, lenacapavir (LEN) ...

The World Health Organization has recommended the use of injectable lenacapavir (LEN) twice a year as an additional ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.